Unlocking The Economics Of AAV Gene Therapy: Why DNA Input Choice Now Matters More Than Ever

As cell and gene therapies scale toward larger patient populations and higher therapeutic doses, the cost of goods (COG) has emerged as a critical bottleneck for commercial viability. Traditional adeno-associated virus (AAV) manufacturing relies heavily on fermentation-based plasmid DNA, an input material that can account for up to 40% of total batch costs.

Transitioning from biological fermentation to advanced, cell-free enzymatic DNA architectures fundamentally alters these economics. Independent financial modeling reveals that eliminating complex bacterial sequences and reducing required DNA input by nearly half can lower overall manufacturing COG by up to 22%. Optimizing the starting material not only enhances process efficiency and capsid purity but also yields millions in annual savings at commercial scale.

Review the comprehensive economic models and optimization scenarios by downloading the full article.